STOCK TITAN

Ocuphire Pharma Inc - OCUP STOCK NEWS

Welcome to our dedicated news page for Ocuphire Pharma (Ticker: OCUP), a resource for investors and traders seeking the latest updates and insights on Ocuphire Pharma.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Ocuphire Pharma's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Ocuphire Pharma's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.31%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.66%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.07%
Tags
management
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.39%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.28%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.94%
Tags
none
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.26%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.28%
Tags
none
Ocuphire Pharma Inc

Nasdaq:OCUP

OCUP Rankings

OCUP Stock Data

45.66M
23.80M
6.98%
15.15%
6.33%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Rockville

About OCUP

ocuphire is a new biopharmaceuticals company focused on developing and commercializing small molecule drugs for unmet medical needs in the ocular disease space. ocuphire’s lead drug candidate, nyxol eye drops, is aimed to treat patients with night vision disturbances (nvd), glaucoma and presbyopia (impaired near-term vision). ocuphire is in discussions with a prospective late stage ophthalmic drug program that could be developed in parallel. ocuphire's management team has over 100 years of drug development expertise across a diverse set of therapeutic areas including ophthalmology, orphan, cardio-metabolic, nephrology, oncology and respiratory.